Best of ASCO - 2014 Annual Meeting

 

Welcome

Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2019 ASCO Annual Meeting but not presented at the Meeting, can be found online only.

Identification of new targets and biomarkers in lung cancer.

Sub-category:
New Targets and New Technologies (non-IO)

Category:
Developmental Therapeutics and Tumor Biology (Nonimmuno)

Meeting:
2019 ASCO Annual Meeting

Abstract No:
e14656

Citation:
J Clin Oncol 37, 2019 (suppl; abstr e14656)

Author(s): Ioannis Papasotiriou, Panagiotis Parsonidis, Dimitrios-Athanasios Ntanovasilis, Aggelos C Iliopoulos, Georgios Beis, Panagiotis Apostolou; Research Genetic Cancer Centre S.A., Florina, Greece

Abstract Disclosures

Abstract:

Background: Lung cancer is the second most common type of cancer in both genders; however is the leading cause of cancer deaths. Adenocarcinoma constitutes more than 60% of non-small cell lung cancer (NSCLC), and accounts for approximately 40% of lung cancers. Therefore, early prediction, prognosis of the disease and treatment strategy is of primary importance. Molecular biology assays, including microarrays, enable identification of new targets. The above targets can be used either as biomarkers, useful for early prediction and prognosis of the disease, or as drugable targets, upon proof of their biological action. The present study aimed to identify new biomarkers and/or targets in lung cancer. Methods: Whole genome gene expression microarrays have been performed for 12 lung cancer cell lines (provided be ECACC, ATCC), representing non-small cell lung (adenocarcinoma, squamous, large cell) and small cell lung cancer. Real-time experiments were followed for validation of thirty genes that were overexpressed. The experiments were performed including other cell lines, representing breast, colon, prostate, hepatocellular, melanoma and pancreatic cancer. Sample from healthy donors, as well as normal lung epithelial cell were used. Results: Among the genes that were studied, there was observed downregulation or none expression in normal donors as well as in normal lung epithelia cells. VSIG10 overexpressed in adenocarcinoma and large cells, while no expression observed in breast, prostate, melanoma and pancreatic cancer. DCBLD2 overexpressed in all NSCLC samples, but not in small cells. LIFR was overexpressed mainly in squamous cells, while no expression or downregulation observed in the other types of cancer. The same expression profile was mentioned for PDGFC. Conclusions: Taking everything into consideration, it is obvious that the identification of new biomarkers and/or targets for lung cancer is of primary importance. The present study revealed different genes, with different biological function that might be used primary as biomarkers. Their role need to be clarified also in clinical samples as to be used as drugable targets. However, the above data are encouraging for identification of new therapeutic models in lung cancer.

 
Other Abstracts in this Sub-Category:

 

1. Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12C inhibitor, in advanced solid tumors.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3003 First Author: Marwan Fakih
Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) - New Targets and New Technologies (non-IO)

 

2. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors.

Meeting: 2019 ASCO Annual Meeting Abstract No: 3007 First Author: Johann S. De Bono
Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) - New Targets and New Technologies (non-IO)

 

3. A phase I study of mirvetuximab soravtansine (IMGN853) and gemcitabine (G) in patients with FOLR1-positive recurrent epithelial ovarian (EOC), endometrial cancer (EC), or triple-negative breast cancer (TNBC).

Meeting: 2019 ASCO Annual Meeting Abstract No: 3009 First Author: Mihaela C. Cristea
Category: Developmental Therapeutics and Tumor Biology (Nonimmuno) - New Targets and New Technologies (non-IO)

 

More...